76,336 results match your criteria Hodgkin Disease


Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.

Authors:
Eden Lake

J Am Acad Dermatol 2018 Dec 3. Epub 2018 Dec 3.

Loyola University Medical Center Dermatology, 321 N La Grange Rd, La Grange Park, IL. Electronic address:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts. Read More

View Article
December 2018
5 Reads

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE, USA.

Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. Read More

View Article
December 2018
5 Reads

Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.

Cell Death Dis 2018 Dec 5;9(12):1178. Epub 2018 Dec 5.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4 T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this heterogeneous group of tumors. Read More

View Article
December 2018

Primary Non-Hodgkin Lymphoma of the Parotid Gland Masquerading Chronic Sialadenitis.

J Craniofac Surg 2018 Nov 30. Epub 2018 Nov 30.

Oral and Maxillofacial Surgery, 8AFDC, Kanpur, India.

View Article
November 2018

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Leuk Lymphoma 2018 Dec 3:1-10. Epub 2018 Dec 3.

a German Hodgkin Study Group (GHSG), Department of Internal Medicine I , University Hospital of Cologne , Cologne , Germany.

We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG's HD13-15 trials with (N = 249) or without (N =900) documented progression or relapse. The participation rate was 52% (N =581). Read More

View Article
December 2018

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.

Br J Haematol 2018 Dec 2. Epub 2018 Dec 2.

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Plasma cells are important prognostic actors in different malignancies. The tumour microenvironmental composition in classic Hodgkin lymphoma (cHL) is a major prognostic key element; however, clinicopathological studies regarding plasma cells in cHL are lacking. The aim of this study was to investigate CD138+ (also termed SDC1+) plasma cell and IgG4 producing (IgG4+) plasma cells infiltration in the microenvironment of cHL. Read More

View Article
December 2018

Where does PD-1 blockade fit in HL therapy?

Authors:
Alex F Herrera

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):213-220

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

Genetic alterations of the / locus on chromosome 9p24.1 are a defining biological feature of classical Hodgkin lymphoma (HL). The resulting programmed death-ligand 1 (PD-L1) expression on Hodgkin Reed-Sternberg cells as well as the PD-L1 expressed in the HL microenvironment result in an ineffective host antitumor immune response and make HL a ripe target for programmed cell death-1 (PD-1) blockade. Read More

View Article
November 2018
2 Reads

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):207-212

Memorial Sloan Kettering Cancer Center, New York, NY.

The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, its high efficacy and favorable toxicity profile led to numerous studies evaluating BV in the front-line, second-line, and posttransplant settings. BV is now approved for use (in combination with chemotherapy) as frontline treatment of advanced-stage patients and as maintenance therapy following autologous stem cell transplant. Read More

View Article
November 2018

Risk-adapted therapy for advanced-stage Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):200-206

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.

More than 80% of patients with advanced-stage Hodgkin lymphoma are now cured with contemporary treatment approaches. The ongoing challenge is how to further improve outcomes by identifying both high-risk patients who may benefit from more intensive frontline therapy to reduce the risk of relapse as well as lower-risk patients who may do just as well with less intensive therapy. Numerous trials have used an interim positron emission tomography (PET) response-adapted approach to evaluate early escalation or deescalation of therapy for patients with a positive or negative interim PET scan, respectively. Read More

View Article
November 2018
1 Read

Novel therapies for relapsed/refractory aggressive lymphomas.

Authors:
Jonathon B Cohen

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):75-82

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

Most patients with aggressive non-Hodgkin lymphoma will be cured with initial chemoimmunotherapy; however, most patients with relapsed disease will not be cured and will die as a result of their disease. In these cases, continued treatment with conventional chemotherapy is typically not of benefit and can contribute to significant toxicities and decreased quality of life for patients. Fortunately, a number of therapies are currently available or under investigation for this group of patients, ranging from oral tyrosine kinase inhibitors targeting multiple pathways within the malignant cells to adoptive cellular therapies that harness the patient's immune system to fight disease. Read More

View Article
November 2018
1 Read

Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis.

Leuk Lymphoma 2018 Dec 3:1-10. Epub 2018 Dec 3.

b Department of Radiation Oncology , University of Colorado School of Medicine , Aurora , CO , USA.

Elderly patients with classical Hodgkin lymphoma (cHL) are understudied and poorly defined. The National Cancer Data Base was queried for adults with cHL diagnosed 2004-2013: 22,547 age 18-39, 12,841 age 40-59, and 10,873 age ≥60 were identified. Two-year overall survival (OS) was 97%, 91%, and 65% for the three age cohorts, respectively (p < . Read More

View Article
December 2018

Voriconazole-Induced Periostitis After Allogeneic Stem Cell Transplantation.

Clin Nucl Med 2018 Dec 3. Epub 2018 Dec 3.

From the Departments of Nuclear Medicine and Molecular Imaging, and.

A 34-year-old man with history of Hodgkin lymphoma presented 7 months after allogeneic stem cell transplantation with an unexplained severe musculoskeletal pain syndrome. A Tc-MDP bone SPECTCT showed multiple foci with moderate to intense bone uptake across the axial and appendicular skeleton consistent with periostitis. The patient had been on voriconazole daily for 4 months to treat an Aspergillus pneumonia, and in the absence of other causes, a drug-induced periostitis was suspected. Read More

View Article
December 2018
3 Reads

Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.

Leuk Lymphoma 2018 Dec 5:1-9. Epub 2018 Dec 5.

a Department of Medicine , University of Toronto , Toronto , Canada.

The association between obesity and survival in non-Hodgkin lymphoma is unclear. Using the Ontario Cancer Registry we conducted a retrospective analysis of incident cases of aggressive-histology B-cell lymphoma treated with a rituximab-containing regimen with curative intent between 2008-2016. 6246 patients were included. Read More

View Article
December 2018
1 Read

Imaging features of extranodal involvement in paediatric Hodgkin lymphoma.

Pediatr Radiol 2018 Dec 5. Epub 2018 Dec 5.

Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children's Hospital, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands.

Detecting extranodal disease in paediatric Hodgkin lymphoma is of great importance for both treatment and prognosis. Different imaging techniques can be used to identify these extranodal sites. This pictorial essay provides an overview of imaging features of extranodal disease manifestation in paediatric Hodgkin lymphoma. Read More

View Article
December 2018

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

BMC Cancer 2018 Dec 4;18(1):1209. Epub 2018 Dec 4.

Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis of the disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor and a putative target for novel immunotherapies. To study patterns of TIGIT expression in the T cell background surrounding malignant cells including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment (ME) tissue microarray (TMA) was constructed from tissue punches measuring 2 mm in diameter obtained from formalin-fixed tissue samples of Hodgkin's lymphoma lymph nodes (n = 40) and normal human tonsil (n = 2). Read More

View Article
December 2018
2 Reads

Lymphome de Burkitt, une urgence diagnostique.

Rev Prat 2016 Jan;66(1):79-82

Service d'hématologie, département de médecine.

Burkitt lymphoma, a diagnostic emergency. Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma. This is the first human tumor where a chromosomal translocation that activates an oncogene (c-myc) has been described. Read More

View Article
January 2016

Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.

Radiology 2018 Dec 4:181519. Epub 2018 Dec 4.

From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-960, Toronto, ON M5G 2M9, Canada (U.M., N.T.); Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada (A.P.); Department of Radiation Oncology, University of Toronto, and Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada (D.C.H.); Cancer Analytics, Analytics & Informatics (M.M., M.E., V.M.), Quality Measurement and Evaluation, Clinical Programs and Quality Initiatives (B.G.), Cancer Imaging, Clinical Programs and Quality Initiatives (P.M.), and Research Office, Analytics & Informatics (N.M., D.L.L.), Cancer Care Ontario, Toronto, ON, Canada; Department of Nuclear Medicine and Molecular Imaging, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (A.S.); and Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston, ON, Canada (J.D.).

Purpose To determine the relationship of PET/CT staging to the management and outcomes of participants with apparent limited-stage (LS) Hodgkin lymphoma (HL) or aggressive non-HL (ANHL) treated with curative intent. Materials and Methods This prospective multicenter registry included 850 participants (467 men and 383 women; median age, 54.1 years) from nine centers who had LS HL or ANHL on the basis of clinical data and CT, or with equivocal CT for advanced stage, who were considered for curative-intent first-line therapy. Read More

View Article
December 2018
1 Read

An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.

Neuropathology 2018 Dec 3. Epub 2018 Dec 3.

Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Progressive multifocal leukoencephalopathy (PML) is a rare fatal demyelinating disease of the central nervous system caused by reactivation of the JC virus (JCV), which is named after the initials of the patient from whom the virus was first isolated. JCV is highly prevalent worldwide, infects humans in early childhood, and the infection persists throughout the course of life in latent form. The present paper deals with the second autopsy case report of rituximab-associated PML in Japan. Read More

View Article
December 2018
2 Reads

High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop.

Cureus 2018 Sep 26;10(9):e3368. Epub 2018 Sep 26.

Internal Medicine, St. Mary Mercy Hospital, Livonia, USA.

Burkitt lymphoma (BL), a highly aggressive B-cell non-Hodgkin lymphoma (NHL), usually presents in children and young adults with large extranodal masses involving jaw bones, gastrointestinal tract, and central nervous system. The three main subtypes of BL are endemic, sporadic, and immunodeficiency variant. Extranodal involvement is common in each variant of BL, although muscle tissue involvement is distinctly rare. Read More

View Article
September 2018
1 Read

A novel model of reno-cardiac syndrome in the C57BL/ 6 mouse strain.

BMC Nephrol 2018 Dec 4;19(1):346. Epub 2018 Dec 4.

Diabetic Kidney Disease Centre, Renal Unit, Barts Health NHS Trust, The Royal London Hospital, Whitechapel Road, London, E1 1BB, UK.

Background: The end stage renal disease population has a 20 fold higher incidence of cardiovascular mortality compared to the overall population. The development of reno-cardiac syndrome in these patients will result in cardiovascular events to be the cause of 50% of fatalities. There is therefore a need to research improved therapeutic strategies to combat renal cardiac pathologies. Read More

View Article
December 2018
5 Reads

Hepatosplenic T-Cell Lymphoma in an Immunocompetent Male with Central Nervous System Invasion: A Rare Clinical Entity.

Cytometry B Clin Cytom 2018 Nov 30. Epub 2018 Nov 30.

Department of Hematology, Hamatological Research Center, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.

Hepatosplenic T-cell lymphoma (HSTCL) is a very rare non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis. Patients of this disease usually presented with hepatosplenomegaly, which can be misdiagnosed or delayed. Bone marrow (BM) and peripheral blood (PB) are frequently involved, however, central nervous system (CNS) involvement is less common. Read More

View Article
November 2018
1 Read

Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT.

MAGMA 2018 Nov 29. Epub 2018 Nov 29.

Department of Diagnostic Imaging, Polish Mother's Memorial Hospital-Research Institute in Lodz, Rzgowska 281/289, 93-338, Lodz, Poland.

Objective: The aim of the study was to evaluate feasibility of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) method in diagnosing Hodgkin lymphoma in pediatric patients and to compare it with 18F-FDG PET/CT as a gold standard.

Materials And Methods: Eleven patients (median age 14) with newly diagnosed Hodgkin lymphoma were examined with 18F-FDG PET/CT and MRI including whole-body DWIBS sequence (b = 0, 800 s/mm), before the oncologic treatment. About 26 locations of lymphatic tissues were evaluated visually and quantitatively using ADC (DWIBS) and SUV (18F-FDG PET/CT), respectively. Read More

View Article
November 2018
4 Reads

Cutaneous B-Cell Lymphoma.

Hematol Oncol Clin North Am 2019 Feb;33(1):149-161

Section of Dermatology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address:

Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. Read More

View Article
February 2019

Mycosis Fungoides and Sézary Syndrome: An Update.

Hematol Oncol Clin North Am 2019 Feb;33(1):103-120

Department of Dermatology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.

Cutaneous T-cell lymphomas are a heterogeneous collection of non-Hodgkin lymphomas that arise from skin-tropic memory T lymphocytes. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common malignancies. Diagnosis requires the combination of clinical, pathologic, and molecular features. Read More

View Article
February 2019
1 Read

Role of PET imaging in adaptive radiotherapy for lymphoma.

Q J Nucl Med Mol Imaging 2018 Dec;62(4):411-419

Guy's Cancer Centre, Guy's & St Thomas' NHS Trust, London, UK.

Positron emission tomography/Computed tomography (PET/CT) is an essential part of modern radiotherapy for patients with lymphoma. PET/CT can be used to adapt treatment algorithms in Hodgkin lymphoma, reserving consolidation radiotherapy for patients with residual fluoro-D-glucose (FDG) avidity after treatment with intensive chemotherapy such as escalated BEACOPP and limiting the need for radiotherapy for some patients with complete metabolic response on PET if radiotherapy may be associated with increased toxicity. More importantly, PET/CT is now mandatory to define sites of initial disease for radiotherapy planning where smaller volumes are to be used rather than historical extended field treatments, such as mantle radiotherapy or even involved field radiotherapy. Read More

View Article
December 2018
1 Read

Trichodysplasia spinulosa in the setting of colon cancer.

Cutis 2018 Oct;102(4):262-264

Silver Falls Dermatology, Salem, Oregon; Department of Dermatopathology, Western University of Health Sciences, Lebanon, Oregon, USA.

Trichodysplasia spinulosa (TS) is a rare skin condition seen in immunosuppressed patients that is characterized by folliculocentric papules with central spiny spicules mainly on the face. We report the case of an 82-year-old woman with a history of treated non-Hodgkin lymphoma and a recent diagnosis of stage IV colon cancer. She presented with clinical and histopathologic findings consistent with TS occurring prior to starting immunosuppressive therapy for colon cancer. Read More

View Article
October 2018
1 Read

Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.

J Cancer Res Ther 2018 Oct-Dec;14(6):1397-1402

Department of Radiation Oncology, Ege University Medical Faculty, Izmir, Turkey.

Background: The most common subtype of aggressive non-Hodgkin Lymphomas is diffuse large B-cell lymphoma (DLBCL). Mediastinal DLBCL is a distinct entity with unique clinical, pathologic, and genetic features and accepted as a subtype of DLBCL. The aim of this study is to evaluate the patients treated with consolidative radiotherapy (RT) after rituximab-containing chemotherapy for mediastinal DLBCL regarding treatment outcomes and relapse patterns. Read More

View Article
November 2018
1 Read

Effect of periodic health exam on provider management of preventive services.

J Eval Clin Pract 2018 Nov 29. Epub 2018 Nov 29.

The Heller School for Social Policy and Management, Brandeis University, 415 South St, Waltham, MA, 02453, USA.

Rationale And Objective: To evaluate the relationship between receipt of annual physicals and the receipt of provider recommendation for preventive services, during a period when Medicare did not cover annual physicals (before 2011).

Methods: Electronic medical records of patients aged 65 years and older from a US health care system were extracted for the 2001 to 2007 period. A fixed-effects logistic model was used to assess the relationship between receipt of periodic health examination (PHE) and receipt of provider recommendation for mammogram screening for 6466 female Medicare beneficiaries. Read More

View Article
November 2018
2 Reads

Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles.

Br J Haematol 2018 Nov 29. Epub 2018 Nov 29.

Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.

View Article
November 2018
2 Reads

Primary Non-Hodgkin Lymphoma of Sphenoid Sinus Involving Cavernus Sinus and Clivus with Isolated 3rd Nerve Palsy.

Mymensingh Med J 2018 Oct;27(4):888-893

Dr Dhiman Chowdhury, Associate Professor, Department of Neurosurgery, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail: dhiman_ns@ yahoo.com.

Lymphomas are group of malignant neoplasm having origins from lymphoreticular cells. B cell Non Hodgkin Lymphoma (BNHL) of sphenoid sinus as primary site for lymphomas are very rare and whenever involves comes usually with ocular manifestations. The proximity of the lesion to optic nerve and cavernous sinus present a high risk of developing unilateral ophthalmoplegia or even blindness. Read More

View Article
October 2018
6 Reads

Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.

J Clin Lab Anal 2018 Nov 28:e22827. Epub 2018 Nov 28.

The Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China.

Background: IgM monoclonal gammopathy can be present in a broad spectrum of diseases. We evaluated the value of serum markers in the differential diagnosis of Waldenstrom macroglobulinemia (WM) and other types of IgM monoclonal gammopathies.

Methods: We included patients who were first admitted to hospital and identified as having IgM monoclonal gammopathy by serum immunofixation electrophoresis (sIFE). Read More

View Article
November 2018
1 Read

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Br J Haematol 2018 Nov 28. Epub 2018 Nov 28.

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a unique rare subtype of Hodgkin lymphoma (HL) which differs clinically, pathologically and biologically from classic HL, warranting a nuanced approach to treatment. CD20 expression by malignant lymphocyte-predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B-cell lymphoma are characteristic features with important implications for treatment and follow-up. Recognition of histopathological variant patterns is also critical, with important implications for prognosis and treatment. Read More

View Article
November 2018
1 Read

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?

Authors:
Lydia Visser

Br J Haematol 2018 Nov 28. Epub 2018 Nov 28.

Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

View Article
November 2018

Therapeutic recommendations for early stage Hodgkin lymphomas.

Br J Haematol 2018 Nov 28. Epub 2018 Nov 28.

Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.

Combined modality treatment has been the standard option for the treatment of early stage Hodgkin lymphoma for several decades. Because of the high success rate and the risk of late toxicities, recent clinical trials have focused on reducing the treatment burden. Field and dose of radiotherapy, and number of cycles of chemotherapy have been successfully reduced, particularly for favourable early stage patients. Read More

View Article
November 2018
3 Reads

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I /II extranodal natural killer/T-cell lymphoma.

Cancer Med 2018 Nov 28. Epub 2018 Nov 28.

Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Background: The optimal treatment for the rare subtype of non-Hodgkin lymphoma, extranodal natural killer/T-cell lymphoma (ENKTL), nasal-type, has not been clearly defined. The purpose of the study was to investigate the efficacy of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy (IMRT) in patients with stage I /II extranodal ENKTL, nasal-type.

Methods: One hundred and fifty-five patients with stage I /II nasal-type ENKTL were enrolled in the study, including 99 patients treated with sequential chemotherapy and extended involved-field IMRT (SCRT) and 56 patients with "Sandwich" chemotherapy and extended involved-field IMRT and chemotherapy (SCRCT). Read More

View Article
November 2018
3 Reads

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.

Front Oncol 2018 13;8:521. Epub 2018 Nov 13.

Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation, Sylvester Comprehensive Cancer Center, Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, United States.

Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor. Despite aggressive multimodality treatment it remains one of the most challenging and intractable cancers (1]. While current standard of care treatment for GBM is maximal safe surgical resection, systemic chemotherapy with Temozolimide (TMZ), and radiation therapy, the current prognosis of GBM patients remains poor, with a median overall survival of 12-15 months (2, 3). Read More

View Article
November 2018
1 Read

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Hematology Department, CHU, Nantes, France; Nantes-Angers Cancer Research Center (CRCINA), University of Nantes, Inserm UMR1232, 8 quai Moncousu, 44007 Nantes, France. Electronic address:

The impact of early Fluorine-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.This retrospective study included all adult Hodgkin (HL) or non-Hodgkin (NHL) lymphoma patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6-9 months) after Allo-SCT in our institution between 2005 and 2015 and who were still without documented progression nor relapse at the time of the FDG PET-CT. All FDG PET-CT were reviewed by a nuclear medicine expert in hematology and restaged according to the Deauville Scale. Read More

View Article
November 2018
1 Read

Reproductive factors, exogenous hormone use and risk of B-cell non-Hodgkin lymphoma in a cohort of women from the European Prospective Investigation into Cancer and Nutrition.

Am J Epidemiol 2018 Nov 27. Epub 2018 Nov 27.

Unit of Molecular Epidemiology and Genetics in Infections and Cancer. Cancer Epidemiology Research Programme. Bellvitge Biomedical Research Institute (IDIBELL). Catalan Institute of Oncology.

The role of hormonal factors in lymphoid neoplasms etiology remains unclear. Previous studies have yielded conflicting results, been underpowered to assess many lymphoma subtypes, or lacked detailed information on relevant exposures. Within the European Prospective Investigation into Cancer and Nutrition cohort, we analyzed comprehensive data collected at baseline (1992-2000) on reproductive factors and exogenous hormone use among 343,458 women, including 1,427 incident B-cell non-Hodgkin lymphomas (NHL) and its major subtypes identified after a mean follow-up of 14 years (through 2015). Read More

View Article
November 2018
4 Reads

Effects of long-term dehydration on oxidative stress, apoptotic markers and neuropeptides in the gastric mucosa of the dromedary camel.

Mol Cell Biochem 2018 Nov 26. Epub 2018 Nov 26.

Department of Pharmacology, College of Medicine and Health Sciences, United Arab Emirates University, PO Box 16103, Al-Ain, UAE.

We investigated the effects of 20 days of dehydration and 20 days of dehydration followed by 72 h of rehydration on the gastric mucosa of the one-humped dromedary camel. The parameters addressed include biomarkers of oxidative stress, apoptosis, gastric epithelial histology, gastric neuropeptides, and their receptors. Nineteen clinically healthy, 4-5 year-old male dromedary camels were divided into three groups (five control camels, eight dehydrated for 20 days, six dehydrated for 20 days and then rehydrated for 72 h). Read More

View Article
November 2018
2 Reads

Primary lymphoma of the skull base in Chinese: clinical, radiological, pathological and therapeutic experience in a series of 8 cases.

World Neurosurg 2018 Nov 23. Epub 2018 Nov 23.

Department of Neurosurgery. Electronic address:

Background: Primary lymphoma of the skull base (PLSB) is an extremely rare neoplasm, and not much is known about the clinical features, treatment strategies and prognoses of these lesions. The aim of this study was to investigate the manifestations and clinical outcomes of patients with PLSB in Chinese.

Methods: We retrospectively reviewed 8 consecutive patients with PLSB treated in our center between October 2008 and December 2016 and analyzed their clinical features, treatment strategies and prognoses. Read More

View Article
November 2018
4 Reads

Do Deauville Scores Improve the Clinical Utility of End-of-Therapy FDG PET Scans for Pediatric Hodgkin Lymphoma?

AJR Am J Roentgenol 2018 Nov 26:1-5. Epub 2018 Nov 26.

1 Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplant, University of Michigan. Medical Professional Bldg D4202, 1500 E Medical Center Dr, SPC 5718, Ann Arbor, MI, 48109.

Objective: The purpose of this study was to evaluate the clinical utility of Deauville scores in interpretation of end-of-chemotherapy FDG PET scans.

Conclusion: Deauville scores improve the clinical utility of end-of-chemotherapy PET, as evidenced by an increase in positive predictive value to 72.7% from 44. Read More

View Article
November 2018
3 Reads

Unusual behavior of diffuse large B-cell lymphoma as cardiac invasion with rapid spontaneous regression after fine needle aspiration cytology.

J Exp Ther Oncol 2018 Nov;12(4):287-290

Cardiology Department, Mansoura Faculty of Medicine, Mansoura University, Egypt.

Objective: Spontaneous regression (SR) of lymphoma is a rare phenomenon. While the precise mechanism of SR remains unknown, apoptosis may be associated with its process. Here, we present a case of a 52-year-old woman was admitted to our hospital with cough and orthopnea for 2 weeks. Read More

View Article
November 2018
5 Reads

Moving things forward in Hodgkin lymphoma.

F1000Res 2018 13;7. Epub 2018 Nov 13.

German Hodgkin Study Group and Department I of Internal Medicine, University Hospital of Cologne, Cologne, 50937, Germany.

Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. Read More

View Article
November 2018

Identification of LEM-14 inhibitor of the oncoprotein NSD2.

Biochem Biophys Res Commun 2018 Nov 21. Epub 2018 Nov 21.

Department of Genetic Engineering, School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea. Electronic address:

The NSD family (NSD1, NSD2/MMSET/WHSC1, and NSD3/WHSC1L1) are histone lysine methyltransferases (HMTases) essential for chromatin regulation. The NSDs are oncoproteins, drivers of a number of tumors and are considered important drug-targets but the lack of potent and selective inhibitors hampers further therapeutic development and limits exploration of their biology. In particular, MMSET/NSD2 selective inhibition is being pursued for therapeutic interventions against multiple myeloma (MM) cases, especially in multiple myeloma t(4;14)(p16. Read More

View Article
November 2018
2 Reads

Efficacy of the GMALL-B-ALL/NHL2002 Protocol in Burkitt Leukaemia/Lymphoma and Aggressive Non-Hodgkin-Lymphomas with or without CNS-Involvement.

Eur J Haematol 2018 Nov 24. Epub 2018 Nov 24.

Department of Haematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Objectives: The GMALL-B-ALL/NHL2002 protocol is effective in Burkitt-lymphoma/leukaemia (BL). Its role in other aggressive lymphomas and in patients with simultaneous central nervous system (CNS) and peripheral involvement is unclear.

Methods: This is a retrospective outcome analysis in 76 patients with BL (n=26), B-lymphoblastic lymphoma (B-LBL; n=3), diffuse large B-cell lymphoma (DLBCL; n=31), mantle-cell lymphoma (MCL; n=6), transformed B-cell non-Hodgkin lymphomas (tB-NHL; n=7) and T-cell NHL (T-NHL; n=3) treated with the GMALL-B-ALL/NHL2002 protocol. Read More

View Article
November 2018
7 Reads

Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.

Cancer Gene Ther 2018 Nov 23. Epub 2018 Nov 23.

Department of Obstetrics and Gynaecology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.

Understanding the molecular mechanisms for the development of non-Hodgkin lymphoma (NHL) will improve our ability to cure the patients. qRT-PCR was applied for the examination of the efficiency of shRNA for DNMT1, the expression of suppressor genes, miRNA-152. The MTT analysis, cell cycle analysis, clonal formation, and apoptotic analysis were used to examine the functions of DNMT1 and miR-152 in lymphoma cells. Read More

View Article
November 2018
1 Read

Rare case of low-grade extranodal NK/T-cell lymphoma, nasal type, arising in the setting of chronic rhinosinusitis and harboring a novel N-terminal KIT mutation.

Diagn Pathol 2018 Nov 23;13(1):92. Epub 2018 Nov 23.

Department of Pathology and Laboratory Medicine, Division of Hematopathology, Hospital of the University of Pennsylvania, 7.018 Gates Pavilion, 3400 Spruce Street, Philadelphia, PA, 19104-4283, USA.

Background: Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT), is a rare aggressive subtype of non-Hodgkin lymphoma characterized by angioinvasion, angiodestruction, necrosis and strong association with Epstein-Barr virus (EBV). ENKTCL-NT occurs worldwide and is more prevalent in Asian and the Native American populations of Mexico, Central and South America. It represents approximately 10% of all peripheral T-cell lymphomas worldwide. Read More

View Article
November 2018
1 Read

Comparison between Cytospin and Liquid-Based Cytology in cerebro-spinal fluid diagnosis of neoplastic diseases. A single institution experience.

Cytopathology 2018 Nov 23. Epub 2018 Nov 23.

Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, Foundation "A. Gemelli" University Hospital, Largo Francesco Vito, 1-00168, Rome, Italy.

Objective: The current tools available for detecting malignant neoplasms in the cerebrospinal fluid (CSF) are neurologic examination, followed by neuroimaging, cytology and molecular techniques. To highlight the role of cytology the diagnosis of metastatic tumors in cerebrospinal fluid (CSF) samples, we present our experience using cytospin and ThinPrep liquid-based cytology (LBC).

Methods: A retrospective analysis was conducted using the pathological records of 8,181 cytological specimens of CSF which were diagnosed over a 17-year period. Read More

View Article
November 2018
4 Reads

Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Br J Haematol 2018 Nov 22. Epub 2018 Nov 22.

Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Allogeneic haematopoietic stem cell transplant (allo-HSCT) offers potentially curative therapy for patients with relapsed/refractory lymphoid malignancies. Reduced-intensity conditioning (RIC) with Alemtuzumab reduces transplant-related mortality and graft-versus-host disease (GvHD), but may be associated with increased risk of relapse. With the aim of studying the effect of GVHD and donor lymphocyte infusions (DLI) on relapse, we performed a retrospective study of 288 patients (57% non-Hodgkin lymphoma, 24% Hodgkin lymphoma and 19% chronic lymphocytic leukaemia; 58% were relapsed/refractory) who underwent RIC-Alemtuzumab-HSCT between 2000 and 2012. Read More

View Article
November 2018
6 Reads

A small change makes a big difference in Hodgkin lymphoma.

Authors:
Martin Hutchings

Blood 2018 Nov;132(21):2214-2215

Rigshospitalet, Copenhagen University Hospital.

View Article
November 2018